Genstar Capital Completes $797 Million Acquisition of PRA International
December 13 2007 - 9:15AM
PR Newswire (US)
SAN FRANCISCO, Dec. 13 /PRNewswire/ -- Genstar Capital, LLC, a
middle market private equity firm that focuses on investments in
selected segments of the life sciences and healthcare services,
industrial technology, business services and software services,
today announced that it has completed its previously announced $797
million acquisition of PRA International (NASDAQ:PRAI), a leading
global clinical research organization. "Our new status as a private
company will enable our entire work force to be even more focused
on attaining our common goal to provide outstanding clinical
research trials for our clients," said Terrance J. Bieker, Chief
Executive Officer of PRA International, who will continue in that
role. "Because of our past successful working relationship with the
Genstar team, we know they will be valuable partners as we work
together to build a strong and lasting company. We look forward to
working with them to grow our business on a global scale."
Stockholders of PRA International approved the transaction at a
special meeting held on December 12, 2007. Stockholders will
receive $30.50 per share in cash for each share of common stock.
The merger was first announced on July 25, 2007. "PRA International
today marks a key milestone as a private company and as the new
owners we look forward to working with Terry Bieker and his
talented management team to build on the company's heritage, strong
industry position, and reputation for unquestionable ethics to help
reach its full potential," said Jean-Pierre L. Conte, Chairman and
Managing Director of Genstar Capital. "We are attracted by the
growth opportunities that exist within PRA International as well as
the overall industry where we continue to target attractive
opportunities." Genstar's current investments in the healthcare and
life sciences sector include OnCURE Medical Corporation, which
owns, operates and manages treatment centers exclusively focused on
providing state-of-the-art radiation treatment alternatives; Harlan
Sprague Dawley, Inc., a leading global provider of preclinical
products and services; and Catalent Pharma Solutions, formerly the
Pharmaceutical Technologies and Services division of Cardinal
Health, the leading contract manufacturing and service provider for
the pharmaceutical industry. PRA International common stock will be
delisted from the NASDAQ Market and trading will be suspended after
the close of the market on Thursday, December 13, 2007.
Stockholders of PRA International who have stock certificates in
their possession will receive instructions by mail from American
Stock Transfer & Trust Company, the paying agent, as to how to
forward their certificates for payment. Credit Suisse Securities
(USA) LLC acted as financial advisor to the PRA International
Special Committee. Dewey & LeBoeuf LLP served as legal advisor
to the Special Committee. UBS Investment Bank and Jefferies acted
as financial advisors, and Latham & Watkins LLP as legal
advisor, to Genstar. About Genstar Capital, LLC Based in San
Francisco, Genstar Capital (http://www.gencap.com/) is a private
equity investment firm that makes leveraged investments in quality
middle- market companies. Genstar Capital works in partnership with
management to transform its portfolio companies into
industry-leading businesses. With more than $3 billion of committed
capital under management and significant experience investing in
businesses, Genstar focuses on selected segments of life science
and healthcare services, industrial technology, business services
and software services. About PRA International PRA International
(http://www.prainternational.com/) is one of the world's leading
global clinical development organizations, with over 3,000
employees working from offices in North America, Europe, South
America, Africa, Australia, and Asia. PRA delivers services to its
clients through a unique approach called Project Assurance(R),
which represents the Company's commitment to reliable service
delivery, program-level therapeutic expertise, easy global access
to knowledge and involved senior management. DATASOURCE: Genstar
Capital, LLC CONTACT: Chris Tofalli of Chris Tofalli Public
Relations, for Genstar Capital, LLC, +1-914-834-4334 Web site:
http://www.prainternational.com/ http://www.gencap.com/
Copyright
Pra (NASDAQ:PRAI)
Historical Stock Chart
From Nov 2024 to Dec 2024
Pra (NASDAQ:PRAI)
Historical Stock Chart
From Dec 2023 to Dec 2024